Lichen planus (LP) is a chronic inflammatory disease of skin and mucous from group of papular dermatosis, less often affecting nails and hair. The article presents photographs of patients with various clinical forms of LP for a more thorough differential diagnosis of this disease.

Erythrodermic mycosis fungoides (eMF) is an atypical severe form of mycosis fungoides resulting from persistent and treatment-resistant disease. eMF manifests as generalized skin bluish lesions, intense itching, secondary lymph-adenopathy, and significant deterioration of quality of life. A differential diagnostic algorithm for various forms of eryth-rodermia is suggested. The paper presents a clinical case of eMF with spots and plaques that skipped the tumor stage. Experience of eMF treatment using vorinostat, gemcitabine, doxorubicin, and alemtuzumab is described.

Aims. To determine the role of regulatory cells (Treg) in patients with vulgar psoriasis (VP) and to provide evidence of its possible role in diagnosis, treatment, and measurement of therapeutic efficacy. Material and methods. We studied 60 patients (35 women and 25 men) with VP, ages ranging from 18 to 55 years. Of these, 28 patients had VP in the progressive stage, 19 were stable, and 8 had resolution of the disease. Overall, 42 patients had VP for less than 20 years and 28 patients for 20 years and more. Patients were divided based on VP severity into the following three groups: mild (10 patients), moderate (22 patients), and severe (28 patients). In addition, the amount of Treg was examined before and after narrow-band ultraviolet-B (UVB) therapy in 12 patients with the progressive stage of VP. The healthy donors (HD) group consisted of 22 persons. Results. A reduction in the number of Treg, CD4+CD25+Foxр3+CD127LOW, was observed in the peripheral blood of patients with VP (2.84% 1.00% for patients with VP and 4.02% 0.73% for HD), with an increase in their number with stage transition (2.59% 0.68% in the progressive stage, 2.82% 1.55% in stable, and 3.68% 1.62% in the resolution period). An inverse correlation was determined not only between the number of Treg and the degree of VP severity (r = -0.39) but also with disease duration (r = -0.46). In addition, NB-UVB phototherapy was noted to promote an increase in the amount of Treg.

Background: The authors presented their own experiences of skin restoration in patients with rosacea after a course of active therapy using transdermal redermalization. Aim: The course of cosmetic correction procedures using this method aimed to restore the energy potential of cells, water balance, and structures of the dermal elastin fibers, normalize microcirculation processes, and create an optimal physiological environment for the mitotic activity of epidermal cells. Materials and methods: An innovative method of transdermal redermalization represents the administration of a drug containing hyaluronic acid and sodium succinate using the technique of papular intradermal injections, taking into account the peculiarities of lymphatic drainage in the facial area. Results: To assess the therapys efficiency, noninvasive monitoring of changes in morphological structures of the skin was performed using confocal laser scanning microscopy. Conclusions: The authors revealed the high efficiency of the method, which controls the remission state for a long term, subsequently avoiding drug therapy

Tumor necrosis factor alpha (TNF-α) is one of the key inflammatory cytokines in the pathogenesis of psoriasis and psoriatic arthritis, and its inhibition with genetically engineered biological drugs ensures control of the main symptoms of these diseases. Certolizumab pegol is a PEGylated (linked to polyethylene glycol) Fab’ fragment of a monoclonal antibody that inhibits human TNF-α. It is approved for treatment of moderate to severe plaque psoriasis and psoriatic arthritis. This review summarizes the results of randomized clinical trials of efficacy and safety of certolizumab pegol in plaque psoriasis (CIMPASI 1, CIMPASI 2, and CIMPACT) and psoriatic arthritis (Rapid-PsA). The represented data demonstrate high efficacy of certolizumab pegol is bio-naïve patients and in patients previously exposed to other TNF inhibitors or IL17 inhibitors. The absence of the Fc-fragment in certolizumab pegol ensures minimal to no placental transfer of the drug and enables its usage during the entire pregnancy.Conflict of interest: the authors state that there is no potential conflict of interest requiring disclosure in this article.